has updated investors on its response to COVID-19 and how it is supporting the NHS through these unprecedented times.
The Company’s Urgent Care division is on the front line responding to an unprecedented number of calls for the NHS’s 111 national triage service, a critical pathway for UK patients of both COVID-19 and other urgent conditions.
In addition, The Company is working with NHS England through additional services including a new service at Heathrow Airport offering specialist support to those arriving into the UK and requiring isolation. The Company continues to work closely with the NHS and Commissioners adding additional services where required and is provisioning new services on a daily basis.
Demand for the Company’s new insourcing business, Totally Healthcare, continues to trade in line with management expectations as all diagnostic procedures still need to go ahead, even though all planned non-urgent operations have been postponed.
The Company is classified as ‘an essential healthcare provider’ with the wellbeing of its staff paramount. In response to COVID-19 the Company has implemented a number of operational changes including the introduction of video consultations in both Urgent and Planned Care situations where possible. Clinicians in Planned Care are stepping forward to support urgent care services and many staff have deferred annual leave to provide support where needed.
Shares in Totally are up 15% following this update.
The Company provides its work via contracts with Commissioners who secure the funding for the delivery of its services and has requested additional funding from the NHS and Commissioners for the additional, enhanced services it is delivering. As the Company approaches its year end, at the end of March 2020, the Board remains confident that the Company's performance will remain strong.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
AstraZeneca said it will be able to supply two billion doses of a potential virus vaccine following two new deals. Last month, AstraZeneca said it could manufacture one billion doses, that it is developing with scientists at Oxford University but yesterday after signing two deals, including one backed by Bill Gates, means it can double production.
Cluff said it is ‘fully committed’ to drilling a Shell-partnered North Sea prospect, but that drilling at the Selene prospect is now expected to start in 2022. Meanwhile, the Company remains fully funded for all its other planned drilling operations.